Opendata, web and dolomites


Title of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje

Total Cost €


EC-Contrib. €






 SEPCELL project word cloud

Explore the words cloud of the SEPCELL project. It provides you a very rough idea of what is the project "SEPCELL" about.

hyperactivation    50    cells    antimicrobial    huge    levels    innovative    bactericidal    possibility    host    exacerbated    sepcell    normal    acquire    acute    experimental    peptides    cell    life    infection    28    threatening    activation    ia    trial    injury    care    severe    possess    inflammatory    benefit    rates    reducing    exaggerated    mechanism    immunoactivation    organ    reported    secondary    vascular    pneumonia    initial    mortality    models    modulate    multiple    believes    social    restoring    functional    pathophysiologic    standard    opportunistic    dysregulation    immune    vasodilatation    anti    infections    msc    patients    leads    medical    capacities    immunoparalysis    complicated    occurrence    micro    community    immunosuppression    sepsis    phagocytosis    dysfunction    homeostasis    performed    systemic    ascs    patient    broad    mediated    subsequent    ss    re    adipose    extensively    mediators    thrombosis    cap    mesenchymal    treatments    clinical    stem    allogeneic    therapy    removal    therapeutic    pro    burden    immunomodulatory    treatment    complete    releasing    vivo    iib    mscs    unmet    lung   

Project "SEPCELL" data sheet

The following table provides information about the project.


Organization address
address: CALLE MARCONI 1
postcode: 28760

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 12˙000˙695 €
 EC max contribution 5˙369˙886 € (45%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2020-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIGENIX SA ES (TRES CANTONS) coordinator 995˙245.00
2    Centre hospitalier universitaire de Limoges FR (Limoges) participant 2˙179˙500.00
5    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 297˙678.00
6    TiGENIX NV BE (LEUVEN) participant 291˙297.00


 Project objective

Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunction. Lung infections, in particular community-acquire pneumonia (CAP), are the leading cause of SS. The pathophysiologic mechanism of CAP-mediated SS is the complete dysregulation of the patient´s immune system. In an initial phase, the systemic hyperactivation of the host immune response against infection leads to high levels of inflammatory mediators, systemic vasodilatation, micro-vascular thrombosis and organ failure. In a second phase, the exaggerated activation of the immune response leads to a state of ‘immunoparalysis’, which is characterized by the occurrence of secondary, opportunistic infections. This makes CAP-mediated SS a life-threatening condition with mortality rates as high as 28-50%. The current standard of care (infection removal and control, functional support) does not improve the high mortality and, thus, CAP-mediated SS represents a major unmet medical need with a huge social burden. Therefore, treatments with the potential to modulate both the initial exacerbated immunoactivation and the subsequent immunosuppression are needed. Mesenchymal stem cells (MSCs), including adipose mesenchymal stem cells (ASCs), are known for their broad range of immunomodulatory properties, targeting multiple pro- and anti-inflammatory pathways, and possess antimicrobial capacities (releasing bactericidal peptides and promoting the phagocytosis by immune cells). Indeed, therapeutic benefit of MSC treatment in in vivo experimental models of sepsis has been extensively reported. The SEPCELL consortium believes that cell therapy with allogeneic ASCs may be an innovative therapeutic approach in order to re-establish the normal immune homeostasis of CAP-mediated SS patients, reducing organ injury and restoring organ functionality. A phase Ia/IIb clinical trial will be performed to test this possibility.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEPCELL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEPCELL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More